Toward characterization and definition of fibromyalgia severity by Silverman, Stuart et al.
RESEARCH ARTICLE Open Access
Toward characterization and definition of
fibromyalgia severity
Stuart Silverman
1, Alesia Sadosky
2*, Chris Evans
3, Yating Yeh
3, Jose Ma J Alvir
2, Gergana Zlateva
2
Abstract
Background: There are no standard criteria for defining or assessing severity of fibromyalgia (FM) as a condition as
fibromyalgia is associated with multiple symptom domains. The objective of this study was to evaluate whether
patient self-reported severity of FM is associated with severity of pain and sleep interference and the presence of
core co-morbidities.
Methods: We recruited individuals ≥ 18 years of age with a clinician-confirmed diagnosis of FM ≥ 3 months and a
current pain rating >2 on a 0-10 numeric rating scale (NRS). Patients completed a questionnaire by mail in which
they self-rated their FM severity (very mild, mild, moderate, and severe), their current pain severity and extent of sleep
interference (NRS; mild, 0-3; moderate, 4-6, severe, 7-10), and provided information (yes/no) on the presence of core
comorbidities (symptoms of depression, anxiety, sleep problems, back pain, neck pain) and medication use for FM.
The core symptoms of FM were stratified to assist with patient characterization. Analysis of variance (ANOVA) was
used to explore the relationship between self-reported FM severity and continuous variables (pain severity and sleep
interference), and Mantel-Haenszel chi-square analysis was used to evaluate the trend in the proportions of patients
reporting use of medications and core symptoms of FM by severity of FM. To complement patient-reported FM
severity and to understand physicians’ perspectives, a survey was performed among 28 physician specialists
(rheumatology, neurology, anesthesiology/pain management, family practice, internal medicine, and psychiatry) to
determine what they assessed when evaluating FM severity in clinical practice.
Results: The population (N = 129) of FM patients was predominantly female (89.1%), with a mean age of 49.4 ± 11.0
years, and 81.4% reported duration ≥ 2 years. Self-reported FM severity was moderate/severe in 86.0% of patients; mean
current pain score was 6.40 ± 2.19 (moderate), and mean sleep interference score was 7.28 ± 2.23 (severe). Greater FM
severity was significantly associated with higher levels of current pain and sleep interference (p < 0.0001), the
proportion of patients reporting FM medication use (p = 0.0001), and the presence of core comorbidities (p < 0.05).
Pain, functional disability, and fatigue severity were ranked as the top three criteria by the highest proportion of
physicians when evaluating FM severity.
Conclusion: With higher self-reported FM severity, patients have greater pain and sleep interference as well as
increased frequency of core comorbidities. Further investigation into understanding FM severity is warranted.
Background
Fibromyalgia (FM) is a disorder of unknown etiology
that is generally diagnosed according to the American
College of Rheumatology (ACR) criteria, which include
chronic, widespread pain for at least 3 months, and the
presence of 11 out of 18 tender points [1]. Prevalence
estimates for the United States suggest that approxi-
mately 5 million individuals have this condition, with a
higher prevalence among women (3.4%) than men
(0.5%) [2]. Although chronic widespread pain is the hall-
mark of FM, core symptoms of FM also include sleep
disturbance, fatigue, mood disorders, and localized pain
(headache, back and/or neck pain). These core symp-
toms are included among the domains that have been
identified and recognized by OMERACT (Outcomes
Measures in Rheumatology) as important for assessment
in FM [3].
FM has a substantial negative impact on quality of life,
resulting in health status that is poorer than other
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osteoarthritis [4-7]. The burden imposed by core FM
symptoms translates into limitations of productivity,
personal and family life, as well as a reduced ability to
complete simple activities of daily living [6,8].
This multidimensional nature of FM has made it diffi-
cult to define and assess the severity of FM as a condi-
tion. The indeterminate etiology and lack of specific
disease markers exacerbate the problem of assessing FM
severity. While several studies investigated the potential
use of biologic markers for FM (e.g. cytokines, antipoly-
mer antibodies), correlation of these markers with symp-
toms was equivocal at best [9-12], rendering them
ineffective as indicators of severity. Similarly, although
tender points and a total myalgic score have been evalu-
ated as measures of severity [13,14], they demonstrate
inherent variability over time [13], show little correlation
with other outcome measures, and importantly, neither
is of clinical relevance to patients. A recent comprehen-
sive review of potential FM biomarkers highlighted the
lack of appropriate evaluation of objective biomarkers of
FM, although limited data from a longitudinal study
suggested that the results obtained during experimental
pain testing were associated with clinical status improve-
ments [15]. However, it should be noted that in addition
to sensitivity to change with clinical improvement, bio-
markers need to demonstrate change with worsening
disease if they are to be considered indicators of disease
severity.
The ability to evaluate and measure the severity of FM
as a condition is likely to provide several benefits
including identification of treatment responders in clini-
cal trials and clinical practice. Characterization of sever-
ity levels may also be used as a marker for disease
progression. Treatment approaches may be specifically
targeted to patients at different levels of severity, with
the potential for determining if early treatment may
slow or prevent disease progression. There have been
few published studies on severity or progression of FM
as a disease state, and what little has been reported
about the natural history of FM is inconsistent.
Although a longitudinal study by Wolfe et al. reported
no change in the severity of specific symptoms over
time [16], a review of the few published studies sug-
gested no clear pattern of progression or remission [17].
Chronic pain is the symptom of FM that is of primary
importance to patients and clinicians and is routinely
evaluated as an endpoint in clinical trials and clinical
practice. Although pain can be quantitatively evaluated
from the patient’s perspective, it may not be an ade-
quate surrogate of disease severity, since it may display
intrapatient variability in intensity which does not neces-
sarily correlate with the presence or severity of other
FM symptoms. A patient-reported instrument frequently
used to assess FM is the Fibromyalgia Impact Question-
naire (FIQ) [18]. Although the FIQ is sensitive to treat-
ment effects [19], it evaluates the impact of FM on
various activities which may be related to, but does not
actually measure, disease severity. Furthermore, the FIQ
appears to have low sensitivity to clinical worsening
[19], and it is unlikely to be an accurate indicator of dis-
ease severity.
In trying to develop a model of FM severity, Golden-
berg et al. [20] evaluated 15 potential explanatory fac-
tors in a regression analysis. Several of the items
evaluated, including pain and psychological distress, may
relate to severity as contributory factors. However,
others such as employment status, pending litigation,
and education level, may be associated with severity in
terms of impact but are not adequate for providing a
definition of FM severity as a disease state.
A study by Giesecke et al. [21] used cluster analysis to
classify patients with FM into subgroups based on levels
of mood, catastrophizing, perceived control over pain,
and tenderness. While this at t e m p ta tc a t e g o r i z a t i o n
demonstrated an ability to place patients into one of
three groups (moderate mood, catastrophizing and per-
ceived pain control with low tenderness; elevated mood
assessment, catastrophizing, and tenderness with low
control over pain; and normal mood and catastrophizing
with high pain control but extreme tenderness), these
results were not placed in the overall context of disease
severity.
The purpose of the current study was to initially char-
acterize FM severity from the perspective of individuals
with FM and to determine if patients’ perception of FM
severity is more than simply their pain. We utilized data
from a larger FM patient study to conduct a post-hoc
exploratory analysis of symptom severity. Data were col-
lected on several self-reported parameters including
patient-rated disease severity and the presence of core
comorbid conditions, we report here the preliminary
evaluation of whether patient self-reported severity of
FM is associated with corresponding severity of pain
and sleep interference and the presence of core co-mor-
bidities. This patient perspective is also complemented
with the results of a small physician survey designed to
understand the physicians’ perspective by capturing
information on what characteristics the physicians use
to assess FM severity in their daily clinical practice.
Methods
Patients were recruited through newspapers, support
groups, and the internet as part of a larger patient
reported outcome study conducted in the US to Patients
were compensated for participation. For inclusion,
patients had to be ≥ 18 years of age with a clinician-
confirmed diagnosis of FM ≥ 3 months (based on a
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could be either specialists or general practitioners, and
was likely dependent upon the duration of FM since
diagnosis. A current pain rating >2 on a 0-10 numeric
rating scale (NRS) from the modified Brief Pain Inven-
tory short form (mBPI-sf) [22] was also required for
inclusion, as was an ability to understand and read Eng-
lish. The presence of rheumatoid arthritis, systemic
lupus erythematosus, or any other chronic pain condi-
tion that would confound the ability to distinguish the
chronic pain from pain related to fibromyalgia was rea-
son for exclusion.
Responses to questions were obtained using a mail-in
mail-back questionnaire. Subjects interested in partici-
pating were mailed the questionnaires in packets con-
taining written instructions on questionnaire completion
and guidance for frequently asked questions. In addition,
a researcher from Mapi Values contacted the subjects to
review the materials and ask if they had questions on
completing the forms. Subjects were also provided a toll
free number to call for study-related questions. All
study screening materials, informed consent, demo-
graphic forms, protocol and other study documents
were submitted and approved by the Copernicus Group
Institutional Revew Board (IRB), an independent IRB
(approval granted on May 10
th 2007).
Patients self-rated their FM severity (very mild, mild,
moderate, and severe) and provided an evaluation of
their current pain severity using the 11-point NRS. Sleep
interference was assessed using the sleep interference
item from the mBPI-sf, a 0-10 NRS that asks “How, dur-
ing the past 24 hours, pain due to your fibromyalgia has
interfered with your sleep?” Cutoff scores of 0-3, 4-6, and
7-10 were used to characterize mild, moderate, and
severe NRS ratings, respectively. These cutpoints were
u s e ds i n c et h e yh a v eb e e np r e v i o u s l yi d e n t i f i e da sb e i n g
optimal for classifying pain in a neuropathic pain condi-
tion (painful diabetic peripheral neuropathy) [23]. Addi-
tionally, the presence of comorbidities was reported by
patients (yes/no for symptoms of depression, anxiety,
sleep problems, back pain, neck pain) as was medication
use for FM (yes/no).
Patient responses and scores were stratified by self-
reported FM severity. Analysis of variance (ANOVA)
was used to explore the relationship between self
reported FM severity and the continuous variables of
pain severity and sleep interference scores, and Mantel-
Haenszel chi-square analysis was used to test for trend
in the proportions of patients reporting use of medica-
tions and core symptoms of FM by severity of FM.
To complement the characterization of FM severity as
reported by patients, the results of a small, separate phy-
sician survey are presented that aimed to explore FM
severity from the perspective of the clinician. This
survey was performed among 28 physicians considered
experts in their respective specialties (rheumatology,
neurology, anesthesiology/pain management, family
practice, internal medicine, and psychiatry). The physi-
cians were asked to respond to the question “When you
assess the severity of fibromyalgia as a condition in your
patients, what are the top 5 items (specific symptoms,
specific physical findings, specific abnormal lab findings,
etc.) that influence your decision-making?” Descriptive
analysis was used to evaluate the rankings by proportion
of physicians reporting each criterion.
Results
Patient-reported severity
A total of 129 patients were enrolled in the study, and
the demographics (Table 1) show that this population
was predominantly female (89.1%), the mean age was
49.4 ± 11.0 years, and almost half the patients (47.3%)
were employed at least part time. The majority of
patients (81.4%) reported FM (≥ 2 years), and
Table 1 Demographic characteristics of the population (N
= 129)
Characteristic Value
Age, y
Mean ± SD 49.4 ± 11.0
Median 50.0
Range 23.0-78.0
Missing data, n (%) 3 (2.3)
Gender, n (%)
Female 115 (89.1)
Male 11 (8.5)
Missing data 3 (2.3)
Employment status, n (%)
Employed full time 38 (29.5)
Employed part time 23 (17.8)
Homemaker 16 (12.4)
Retired 11 (8.5)
Unemployed 11 (8.5)
Other 25 (19.4)
Missing data 5 (3.9)
Duration of fibromyalgia, n (%)
3 months-1 year 20 (15.6)
2-5 years 44 (34.1)
6-10 years 28 (21.7)
> 10 years 33 (25.6)
Missing data 4 (3.1)
Current pain severity
a
Mean ± SD 6.40 ± 2.19
Range 0.0 - 10.0
Median 7.0
Missing data, n (%) 13 (10.1)
a 0-10 numerical rating scale from the short form Modified Brief Pain
Inventory
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FM > 10 years.
While 111 patients (86.0%) reported their FM severity
as being of at least moderate intensity (45.7% moderate
and 40.3% severe), 3 patients (2.3%) and 12 patients
(9.3%) reported very mild and mild severity, respectively.
Due to the low number of patients in the very mild
category, this category was collapsed into the mild cate-
gory representing 15 patients (11.6%). Data were missing
for 3 patients (2.3%). The mean NRS scores from the
mBPI-sf suggested current pain of moderate severity
(6.40 ± 2.19), and pain-related sleep interference that
w a ss e v e r e( 7 . 2 8±2 . 2 3 ) .A ss h o w ni nF i g u r e s1 Aa n d
1B for both of these outcomes, with greater self-
reported FM severity, there was a corresponding
increase in pain severity and sleep interference. ANOVA
analysis suggested that this higher FM severity was sig-
nificantly associated with the increase in current pain
(F [2, 113] = 21.10, p <0.0001 and sleep interference
(F [2, 113] = 15.4, p <0.0001). Sleep interference scores
were higher (i.e. greater severity) than pain scores at all
levels of FM severity.
Similarly, at higher levels of self-reported FM severity,
t h e r ew a sac o r r e s p o n d i n gi n crease in the proportion of
patients who used medications for their FM and who
reported core comorbidities including sleep problems,
depression and anxiety, and back and neck pain (Table 2).
Among patients with severe FM, 90% had sleep problems
and 84% were using medications for FM. Even among
patients with mild FM, sleep problems were reported by
40% of the patients, and prescription medications for FM
were used by approximately one quarter (26.7%) of the
patients. For nearly all levels of FM severity, the propor-
tion of patients reporting symptoms of depression was
similar to the proportion reporting symptoms of anxiety.
The exception was for mild FM, of which a higher propor-
tion of patients (20.0%) reported symptoms of anxiety rela-
tive to depression (6.7%). Mantel-Haenszel chi-square tests
suggested that the trends observed with increasing self-
reported severity were significant for medication use and
all core comorbidities (Table 2).
FM severity was also significantly associated with
duration of FM since initial diagnosis (Figure 2; Chi-
square = 27.22; df = 6; p = 0.0001). The majority of
patients who reported mild FM (60%) had been diag-
nosed with FM during the previous year, and conversely,
94% of patients with FM duration ≥ 2 years since diag-
nosis reported moderate to severe FM.
Physician reported severity
W h e na s k e dt op r o v i d ear a n k e dl i s to ft h et o p5i t e m s
that contribute to decision-making when evaluating
patients with FM, physicians listed a variety of criteria that
they use for assessing FM severity. Table 3 presents the
results of the survey by arranging the items according to
the highest proportion of physicians who gave a desig-
nated rank to a specific symptom. Pain, functional disabil-
ity, and fatigue severity were ranked as the top three
criteria by the highest proportion of physicians. The great-
est concordance was for pain, which was ranked as the top
criterion by 17 of the 28 physicians (61%), although physi-
cians also cited several other factors considered as primary
criteria, including the Fibromyalgia Impact Questionnaire
score, functional disability, and tender points. While sleep
disruption was not included in the top three criteria, it
was nevertheless used as a criterion of FM severity by 43%
of physicians, as were the presence of comorbidities (32%)
and duration of symptoms (18%).
Figure 1 Relationship between self-reported fibromyalgia severity and current pain (A) and pain-related sleep interference (B). Values
represent mean scores (± standard deviation as shown by the vertical bars) from the short form of the modified Brief Pain Inventory. P values
are for the overall association between fibromyalgia severity and levels of current pain and pain-related sleep interference using ANOVA.
Silverman et al. BMC Musculoskeletal Disorders 2010, 11:66
http://www.biomedcentral.com/1471-2474/11/66
Page 4 of 9Discussion
This study suggests that the association of FM severity
with symptoms that have been identified as being of clini-
cal importance by patients and physicians [3], and are con-
sidered by OMERACT to be among the core FM
symptoms for evaluation [3,24], may be useful for the
characterization and assessment of the severity of FM as a
condition. In particular, with higher self-reported FM
severity, i.e. from mild to moderate to severe, an associated
increase was observed in pain, sleep disturbance, and
depressive symptoms, as well as the use of medications for
FM and the presence of comorbid conditions including
back and neck pain. Therefore, these characteristics may
contribute to the patient’s overall perception of disease
severity.
Determining a definition of FM severity could be help-
ful for disease management. A definition based on the
patient’s perspective may be especially useful, since in
the absence of objective disease biomarkers it relies on
readily available information of clinical relevance to the
patient that can be used by physicians for patient classi-
fication and management. The only other study that
attempted to develop a severity model also used a
patient-reported outcome, global VAS, as the anchor for
FM severity [20]. While the current study did not use a
validated measure, the anchor for FM severity was a
question specifically addressing FM rather than a global
assessment.
The use of patient self-report is increasingly being
accepted and applied as a method to evaluate disease
states and management strategies in clinical trials, espe-
cially for chronic pain conditions [25]. This has been
true for the rheumatic diseases including FM, for which
most of the core domains considered by OMERACT as
being essential for evaluation, are patient-centric [3,24].
T h et o pf i v eo ft h e s ed o m a i n si n c l u d ep a i n ,f a t i g u e ,
patient global, sleep, and multidimensional function.
These domains are generally the same as those identi-
fied as being important by patients, i.e. pain or physical
Table 2 Relationship between self-reported fibromyalgia
severity and proportion of patients reporting use of
medications and core symptoms of fibromyalgia (FM).
Binary Variable Self-reported FM
severity
(percent of patients)
Mantel-Haenszel
Χ
2
(P value)
Mild Moderate Severe
Medications for FM 26.7 65.5 84.0 16.54 (< 0.0001)
Sleep problems 40.0 72.9 90.4 15.99 (< 0.0001)
Symptoms of
depression
6.7 52.5 65.4 13.14 (< 0.001)
Symptoms of anxiety 20.0 52.5 61.5 6.56 (< 0.05)
Back pain 46.7 72.9 82.7 6.90 (< 0.01)
Neck pain 26.7 72.9 71.2 5.52 (< 0.05)
Mantel-Haenszel chi-square tests for trend (d.f. = 1) of the proportions of
patients reporting use of medications and core symptoms of fibromyalgia by
severity of fibromyalgia.
Figure 2 Relationship between duration of fibromyalgia and patient self-reported fibromyalgia severity. The percentages reflect the
proportion of patients with the indicated duration of fibromyalgia who were at each self-reported severity level (e.g. of patients with
fibromyalgia < 1 year, 45% reported mild disease). Chi-square = 27.22, df = 6; p = 0.0001.
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gue, effects on sleep, and problems with attention or
concentration [3,24]. Patients may have a better sense of
their condition than can be obtained using objective
clinical criteria, and at least in some rheumatic condi-
tions, patient-centered outcomes may also discriminate
between placebo and active treatment as well as or bet-
ter than objective clinical measures [26-28].
While two factors identified in this exploratory analysis,
i.e. pain and depression, were previously identified by
Goldenberg et al. [20] as having a potential relationship
with FM severity, the results reported here also suggest
that overall, patients with longer FM duration tended to
report greater FM severity. However, it should be noted
that there was a small increase in the proportion of
patients reporting mild severity among the patients with
FM duration > 10 years relative to those having a shorter
duration. Although the reason for this increase was not
explored, it could potentially be due to adaptation or a
greater ability to cope with a chronic condition among
some patients. This is consistent with what was reported
by Kennedy et al. [29] in one of the few long-term
(10-year) follow-up of patients with fibromyalgia; at
10 years, despite the presence of symptoms that showed
little change from the initial survey and continued use of
medication, a substantial proportion of patients reported
that they felt better in terms of FMS symptoms.
The observed relationship between FM severity and
duration is in contrast to Goldenberg et al. [20] who
reported that there was no relationship between these
variables. Their observation may potentially result from
use of a global assessment rather than a more specific
FM assessment [20]. Similarly, the results reported here
diverge from a previous study which reported that
symptom severity does not change over time [16]. How-
ever, that study used more compressed assessment
scales for sleep disturbance and pain (0-3 visual analo-
gue scales) than the current study (0-10 NRS) and did
not stratify patients by FM duration. If such an associa-
tion between duration and severity can be confirmed, it
may provide an opportunity to identify patients early in
the disease continuum and eventually modify or delay
disease progression through the use of pharmacological
and/or non-pharmacological interventions.
The observation that the NRS scores for sleep distur-
bance were higher than NRS pain scores across all levels
of FM severity appears to be consistent with a recent
analysis showing that sleep problems were predictive of
pain [30], although it is unlikely that the relationship
between sleep and pain is unidirectional. However, the
data do suggest that these two variables may be central,
although not exclusive, components for defining severity
of FM, and that management of both pain and sleep
problems are integral to the treatment of FM.
Table 3 Ranked criteria reported by physicians for assessing fibromyalgia severity (N = 28) based on the open-ended
question “When you assess the severity of fibromyalgia as a condition in your patients, what are the top 5 items
(specific symptoms, specific physical findings, specific abnormal lab findings, etc.) that influence your decision-
making?”
Ranked criteria, n (%) of responses
#1 #2 #3 #4 #5
Pain*, 17 (60.7) Functional disability, 6 (21.4) Fatigue, 4 (14.3) Functional disability, 4 (14.3) Fatigue severity, 3 (10.7)
FIQ, 3 (10.7) Pain, 4 (14.3) Functional disability, 3 (10.7) Presence of comorbidities,
4 (14.3)
Duration of symptoms,
1 (3.6)
Functional disability,
2 (7.1)
Sleep disruption, 4 (14.3) Sleep disruption, 3 (10.7) Sleep disruption, 3 (10.7) Pain, 1 (3.6)
Tender points, 2 (7.1) Duration of symptoms,
3 (10.7)
Presence of comorbidities,
3 (10.7)
Fatigue severity, 2 (7.1) Sleep disruption, 1 (3.6)
Fatigue, 1 (3.6) Tender points, 2 (7.1) Pain, 2 (7.1) Pain, 1 (3.6) Global assessment,1 (3.6)
QoL, 1 (3.6) Presence of comorbidities,
2 (7.1)
Tender points, 2 (7.1) QoL, 1 (3.6) Tender points, 1 (3.6)
Sleep disruption, 1 (3.6) Fatigue, 1 (3.6) QoL, 1 (3.6) Other, 5 (17.9) Number of medications,
1 (3.6)
Clinical history, 1 (3.6) FIQ, 1 (3.6) Duration of symptoms, 1 (3.6) None listed, 7 (25.0) Other, 7 (25.0)
HAQ, 1 (3.6) Global assessment, 1 (3.6) None listed, 12 (42.9)
Other
†, 2 (6.9) Number of medications,
1 (3.6)
None listed, 1 (3.6) Other, 4 (14.3)
FIQ, Fibromyalgia Impact Questionnaire; QoL, Quality of life; HAQ, Health Assessment Questionnaire. *Pain includes intensity and/or quality characteristics.
†“Other” category includes laboratory abnormalities, cognitive/behavioral status, psychological impact, work status
Columns are ordered by decreasing rank, rows are ordered by the proportion of physicians designating a particular numerical rank for the specific symptom.
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ended and elicited severity information based on specific
symptoms and comorbidities, the physician survey was
open-ended. This physician survey demonstrated that,
consistent with the absence of an adequate definition of
FM severity, there was a general lack of consensus
regarding criteria that physicians use as an indicator of
F Ms e v e r i t y .T h a tp a i nw a st h em o s tf r e q u e n t l yu s e d
criterion of severity was not surprising considering that
pain is often the primary complaint of patients with FM.
However, despite being ranked first as an indicator of
severity, only 61% of the physicians considered pain the
primary criterion. There was little concordance on the
use of other criteria, including several of the factors that
demonstrated a relationship with higher levels of self-
reported FM severity, i.e. sleep interference and the pre-
sence of comorbidities, which were identified by only
43% and 32% of physicians, respectively. The small sam-
ple size (N = 28) may have contributed to this lack of
concordance.
Although functional disability was ranked second and
fatigue was ranked third, these criteria were used overall
by 54% and 39% of physicians, respectively. These parti-
cular criteria, although identified by physicians, were not
assessed in patients as part of the patient survey, and
may be considered a limitation of the study, especially
since fatigue is a frequent complaint among patients
with FM [31]. Indeed, while the patient and physician
surveys provide complementary information regarding
perceptions of FM severity, the different manner in
which the surveys were performed precludes comparison
of these surveys, since patients were asked to rate sever-
ity but were not asked to rank symptoms.
Since physicians identified and ranked criteria in
response to a question ("When you assess the severity of
fibromyalgia as a condition in your patients, what are
the top 5 items [specific symptoms, specific physical
findings, specific abnormal lab findings, etc.] that influ-
ence your decision-making?”), physicians were not speci-
fically queried as to how these assessments are made. It
should be noted that objective clinical assessment using
tender points was cited by only 18% of the physicians,
and that nearly all the other criteria were patient-cen-
tric. The variety of criteria that these physicians, who
routinely treat FM patients, reported using and the lack
of concordance on their use, reinforces the need to
define what constitutes an adequate measure of FM
severity. Being able to define and measure FM severity
may have practical benefits in terms of understanding
disease progression and evaluating treatment approaches
for their potential ability to slow progression. The ability
to slow progression is likely to have a broader clinical
and economic impact by reducing health resource utili-
zation and associated costs.
This was an exploratory, post-hoc analysis and is sub-
ject to several limitations. As part of the eligibility cri-
teria, participants were required to have a minimum
level of pain, i.e. a current pain rating of at least 2 on a
0-10 NRS. In addition to the small sample size, this
inclusion criterion may have selected against patients
who would likely have self-reported very mild or mild
disease. In fact the proportion of patients in this study
who reported these levels of FM severity was small
(11.6%), and these levels were mainly associated with
FM duration ≤ 1 year, for which the proportion of
patients was also correspondingly small (15.9%). Because
of these low proportions, the current analysis may have
had limited power to evaluate correlations at this end of
the severity spectrum.
Furthermore, while the assessments were specific for
the variables measured, only single items were used for
most of the variables, potentially restricting interpreta-
tion of our findings. Additionally, for those outcomes
evaluated based on an NRS score (i.e. pain and sleep
interference), there is no validation of cutoff scores des-
ignating severity levels. Therefore, it cannot be defini-
tively stated that a particular self-reported FM severity
level correlated with a similar severity of pain or sleep
interference. However, extrapolation of pain ranges for
the mBPI-sf (mild 0-3, moderate 4-6, severe 7-10) that
were validated for a neuropathic pain condition, diabetic
peripheral neuropathy [23], suggests that these out-
comes were of at least moderate intensity even among
FM patients who self-reported mild FM.
The fact that patients were compensated for participa-
tion may have introduced additional bias, since it is not
k n o w nw h a te f f e c tt h eu s eo fc o m p e n s a t i o nm a yh a v e
had on the selection of patients. Consequently, the
results reported here may not be generalizable to the
overall FM population. The small number of patients,
although representative of various regions of the US,
may also contribute to the lack of generalizability. There
were a disproportionate number of female participants,
with the implication that gender bias may have skewed
the data, since gender differences may be operative in
the perception and report of pain as well as in the
determinants that contribute to self-rated health status
[32-34]. However, the sex ratio in this study is not only
reflective of FM in clinical practice, but complements
the reporting that few gender differences exist in the
severity or range of symptoms for FM including pain
severity, physical function, and psychological factors
[35].
Conclusions
This study explored the patient and physician perspec-
tive of FM severity. With greater patient reported FM
severity, there was an increase in other patient reported
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of comorbid conditions and use of medications for FM.
This study also suggests that physicians use different
domains to rank FM severity. Both these findings need
to be validated in further studies. When evaluating
severity of FM, physicians should consider the patient
perspective.
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